Skip to main content
. 2017 Apr 19;8(31):51238–51252. doi: 10.18632/oncotarget.17228

Figure 4. hG7-BM3 enhanced PBMCs or NK92-FcR cells cytotoxicity.

Figure 4

(Ai to iv) Cytotoxicity assay to assess the PBMC/NK92 cell-mediated killing of hepatoma cell cells. The EC50 of hG7-BM3 were fitted. (Bi to iv) Huh-7 and BEL-7402 were used as target cells and PBMC/NK92 cells as effect cells for a LDH release assay. The E:T ratios were indicated. The equivalent dose of rG7S with no Fc domain was used as scFv group. (Ci to iv) The increase of cell lysis was enhanced significantly upon treatment with hG7-BM3 compared to control groups or scFv group and unchanged upon treatment with hG7-BM3 compared to cG7. Data were given as the mean ± SD (n = 5). *p < 0.05, ***p < 0.001, ns: no significance.